ASCO 2016: Updated Data of MOR202 for Multiple Myeloma Presented by MorphoSys
In a poster presentation at the 2016 ASCO Annual Meeting in Chicago, MorphoSys presented updated safety and efficacy data from an ongoing open-label, multicenter, Phase…
Myeloma
Clinical Results of Selinexor Combo Regimen for Multiple Myeloma Presented by Moffitt Cancer Cancer at ASCO 2016
The Moffitt Cancer Center has completed a Phase 1 clinical trial of selinexor combined with liposomal doxorubicin and dexamethasone for the treatment of…
European Commission Approves Janssen’s Multiple Myeloma Treatment Darzalex (Daratumumab)
The European Commission (EC) has granted provisional approval to Janssen’s Darzalex (daratumumab) as a monotherapy for the treatment of patients with multiple myeloma who…
New Clinical Trial for Multiple Myeloma Patients to Evaluate Safety and Efficacy of SurVaxM Vaccine
An immune-based vaccine created by researchers at Buffalo, New York’s Roswell Park Cancer Institute (RPCI) is now moving to its third study. The new…
Iceni Planning a Phase 2 Study of Cilengitide in Multiple Myeloma Patients
Iceni Pharmaceuticals, formerly known as Big DNA Ltd., announced plans to soon begin testing its lead product Cilcane (cilengitide) as a first-in-class treatment for multiple…
Myeloma Foundation Claims Controversial Drug Report Could Limit Access to Best Treatments
The International Myeloma Foundation (IMF), the largest organization focusing specifically on multiple myeloma (MM), is now alerting that a reportedly flawed document evaluating…
Data on Combo Therapy for Multiple Myeloma to Be Presented by PharmaMar at ASCO Meeting
Positive data for the Phase 1 trial of PharmaMar’s plitidepsin combined with bortezomib and dexamethasone for the treatment of relapsed and/or refractory multiple…
Amgen to Present New Data on Kyprolis, a Multiple Myeloma Treatment, at EHA 2016
Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The…
New Data on Myeloma Drug Candidates to Be Presented by PharmaMar at Oncology Meeting
Spain-based PharmaMar announced the company will present data from several clinical studies of three of its anti-tumoral compounds of marine origin — plitidepsin, Yondelis (trabectedin),…
Phase 3 Study of Stem Cell Transplantation in Multiple Myeloma Patients Showing Early Benefits
Results from an ongoing clinical trial supports the use of upfront autologous stem cell transplantation (ASCT) to treat multiple myeloma patients age 65 or younger.
